about
Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysisDual antiplatelet therapy: optimal timing, management, and durationPrasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study.Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study.Coronary revascularization in the diabetic patient.Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC study.Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial.EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT).Incidence and consequence of major bleeding in primary percutaneous intervention for ST-elevation myocardial infarction in the era of radial access: an analysis of the international randomized Acute myocardial infarction Treated with primary angioplImpact of renal failure on all-cause mortality and other outcomes in patients treated by percutaneous coronary intervention.Switching acute coronary syndrome patients from prasugrel to clopidogrel.TTR sequencing should be considered ahead of hypertrophic cardiomyopathy in Afro-Americans.The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up.Intravenous enoxaparin anticoagulation in percutaneous left atrial cardiac procedures.Contrast-induced acute kidney injury and mortality in ST elevation myocardial infarction treated with primary percutaneous coronary intervention.Triple antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention.Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial.Periprocedural myocardial infarction and injury in elective coronary stenting.Anticoagulation in acute coronary syndrome-state of the art.Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial.Silent Myocardial Infarction: Listen to the Evidence.Outcome after revascularisation of acute myocardial infarction with cardiogenic shock on extracorporeal life support.Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study.Sex-related differences after contemporary primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial.Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome.Conundrum of Using Real-World Observational Data to Inform Real-World Conclusions About Safety and EfficacyMost Promising Therapies in Interventional Cardiology
P50
Q22242057-F00B16C4-1904-4037-9B8E-0E619BAFBDADQ26741055-995B9264-CE1A-4F90-B88C-2D575B81E9EBQ35204942-778E3CE0-70CA-46BA-9079-A4FA6492C213Q35675096-DE27E4B1-13B1-4BA8-8627-F31EEA55AB33Q36244001-DB210BEF-8B06-4864-8B4C-2B98C48EE15CQ38246957-6F57676F-F986-448E-9A4B-0B5786A88B06Q38400425-3495CEDA-182C-4FC4-BE17-DB2B4D337E02Q38432477-C0D71E75-7D0F-401E-898D-6073EA4C0AC3Q38637360-1A697FC8-1AE4-4815-8867-13FFA48D93C8Q40583948-62B13C55-58BF-42EE-9E46-1576CFDE495BQ41343198-307D01C7-FE15-46D2-8CAC-A232906690B9Q41577137-51AA3681-E4DE-4F6D-A978-CF9BC884475DQ43685527-2E7D21A4-00F0-4E4E-B506-3E789A031EA2Q45851341-007AFBE3-90D2-4A93-8D92-C4084B7F83D2Q47674466-9A95DD62-9AAA-400C-B85E-F6068A6BADB8Q47799540-980810C1-0196-4FD9-BB43-4D33C79E3C28Q48380440-E6CFA52C-E62F-448F-8352-07B8CB98AFD2Q49346157-C7D9DFB6-F25F-4CA4-9B42-CBC8C2E4CA03Q49502488-B5FCCB81-7C04-47F8-8670-2F78AA2F7D1CQ49819606-C9DCFFE7-FE1D-4319-BD4B-E6CF829EE357Q50021337-E156E376-D455-481A-ABF2-D0F475B13901Q50048393-8F40E998-E1C9-4128-B069-FE57FA00FAEAQ50188675-4F69D1F0-EEC6-48E1-8F5A-58BCA41890B9Q50199837-CD8365B9-D6E7-46F1-A383-511794934FF5Q50868428-639FC8A5-F129-4C75-93E6-1D9FF2B40268Q51027956-75E0280C-A9DF-49EE-BFB5-035027FFB848Q51067690-4906CDD1-48B2-4EFD-86EA-367411F44495Q52650835-D51B3608-3551-4497-B6D4-B08AD94460C7Q53326333-B3FDA753-5EF2-445C-BBB9-457D1603F1D8Q57025372-09B8763D-5BB9-4A68-9A18-653897A63B34Q62489343-8E43C9E7-F8D0-4F7A-BD34-184ECA0D5EDF
P50
name
Mathieu Kerneis
@en
Mathieu Kerneis
@nl
type
label
Mathieu Kerneis
@en
Mathieu Kerneis
@nl
prefLabel
Mathieu Kerneis
@en
Mathieu Kerneis
@nl